text: Yo, listen up, I got a story to tell,
  'Bout pediatric ALL, a treatment that don't end well.
  They use 6-thioguanine, known as 6-TG,
  But it comes with hepatic SOS, can't you see?
  
  The treatment's long-term, but the outcome's grim,
  High rates of obstruction syndrome, it's not a whim.
  They keep it short, sparse info on toxicity,
  But we gotta analyze the association explicitly.
  
  3983 patients, pediatric ALL,
  On trial AIEOP-BFM ALL 2000, we stand tall.
  We looked at hepatic SOS, a serious adverse event,
  And the role of TPMT genotype, that's what we represent.
  
  We found 17 patients, SOS was their fate,
  13 had short-term exposure, it's a heavy weight.
  P less than 0.0001, the risk was clear,
  Short-term 6-TG got 'em, no need to fear.
  
  Out of those 13, 8 had low-activity TPMT,
  Heterozygotes faced a risk, can't you see?
  Their chances increased, 22.4-fold,
  SOS was lurking, a story yet untold.
  
  We replicated the results, they stood true,
  Independent analysis, the evidence grew.
  But here's the silver lining, let's not forget,
  All patients recovered, no symptoms left.
  
  So there you have it, the tale of 6-TG,
  Pediatric ALL and hepatic SOS, you see.
  Short-term exposure, a risk for sure,
  Especially for patients with low-activity TPMT genotype, that's the cure.